H Nina Kim1, Robin Nance, Stephen Van Rompaey, Joseph C Delaney, Heidi M Crane, Edward R Cachay, Elvin Geng, Stephen L Boswell, Benigno Rodriguez, Joseph J Eron, Michael Saag, Richard D Moore, Mari M Kitahata. 1. Departments of *Medicine; †Epidemiology, University of Washington, Seattle, WA; ‡Department of Medicine, University of California-San Diego, San Diego, CA; §Department of Medicine, University of California-San Francisco, San Francisco, CA; ‖Department of Medicine, Harvard University, Fenway Health, Boston, MA; ¶Department of Medicine, Case Western University, Cleveland, OH; #Department of Medicine, University of North Carolina, Chapel Hill, NC; **Department of Medicine, University of Alabama, Birmingham, AL; and ††Department of Medicine, Johns Hopkins University, Baltimore, MD.
Abstract
BACKGROUND: Liver disease is a major cause of mortality among HIV-infected persons. There is limited information about the extent to which HIV disease severity impacts liver disease progression. METHODS: We determined the incidence and predictors of advanced hepatic fibrosis measured by the Fibrosis-4 index (≥3.25) in a large diverse population of HIV-infected patients without significant liver disease at baseline (Fibrosis-4 score <1.45) in care between January 2000 and March 2014. We used Cox proportional hazards analysis to examine factors associated with progression to Fibrosis-4 score ≥3.25. RESULTS: Among 14,198 HIV-infected patients, hepatitis C virus (HCV) coinfection [adjusted hazard ratio (aHR) 1.9, 95% confidence interval (CI): 1.6 to 2.1], hepatitis B virus coinfection (aHR 1.5, 95% CI: 1.2 to 1.8), alcohol-use disorder (aHR 1.4, 95% CI: 1.2 to 1.6), and diabetes (aHR 1.9, 95% CI: 1.6 to 2.3) were associated with progression to advanced fibrosis in multivariable analysis. In addition, patients at each lower level of time-varying CD4 cell count had a significantly greater risk of progression, with ∼7-fold higher risk in those with CD4 <100 cells per cubic millimeter (aHR 6.9, 95% CI: 5.8 to 8.3) compared with CD4 ≥500 cells per cubic millimeter. An increasing gradient of risk was also observed among patients with higher time-varying HIV viral load (VL), with the greatest risk noted with VL ≥100,000 copies per milliliter (aHR 2.6, 95% CI: 2.2 to 3.1) compared with VL <500 copies per milliliter. CONCLUSIONS: Lower CD4 cell count and higher HIV VL were significantly associated with progression to advanced hepatic fibrosis in a dose-dependent manner, independent of the risk associated with traditional factors: hepatitis C virus or hepatitis B virus coinfection, alcohol, and diabetes. Our findings suggest that early treatment of HIV infection could mitigate liver disease.
BACKGROUND:Liver disease is a major cause of mortality among HIV-infectedpersons. There is limited information about the extent to which HIV disease severity impacts liver disease progression. METHODS: We determined the incidence and predictors of advanced hepatic fibrosis measured by the Fibrosis-4 index (≥3.25) in a large diverse population of HIV-infectedpatients without significant liver disease at baseline (Fibrosis-4 score <1.45) in care between January 2000 and March 2014. We used Cox proportional hazards analysis to examine factors associated with progression to Fibrosis-4 score ≥3.25. RESULTS: Among 14,198 HIV-infectedpatients, hepatitis C virus (HCV) coinfection [adjusted hazard ratio (aHR) 1.9, 95% confidence interval (CI): 1.6 to 2.1], hepatitis B virus coinfection (aHR 1.5, 95% CI: 1.2 to 1.8), alcohol-use disorder (aHR 1.4, 95% CI: 1.2 to 1.6), and diabetes (aHR 1.9, 95% CI: 1.6 to 2.3) were associated with progression to advanced fibrosis in multivariable analysis. In addition, patients at each lower level of time-varying CD4 cell count had a significantly greater risk of progression, with ∼7-fold higher risk in those with CD4 <100 cells per cubic millimeter (aHR 6.9, 95% CI: 5.8 to 8.3) compared with CD4 ≥500 cells per cubic millimeter. An increasing gradient of risk was also observed among patients with higher time-varying HIV viral load (VL), with the greatest risk noted with VL ≥100,000 copies per milliliter (aHR 2.6, 95% CI: 2.2 to 3.1) compared with VL <500 copies per milliliter. CONCLUSIONS: Lower CD4 cell count and higher HIV VL were significantly associated with progression to advanced hepatic fibrosis in a dose-dependent manner, independent of the risk associated with traditional factors: hepatitis C virus or hepatitis B virus coinfection, alcohol, and diabetes. Our findings suggest that early treatment of HIV infection could mitigate liver disease.
Authors: Daniel Grint; Lars Peters; Juergen K Rockstroh; Aza Rakmanova; Tatiana Trofimova; Karine Lacombe; Igor Karpov; Massimo Galli; Pere Domingo; Ole Kirk; Jens D Lundgren; Amanda Mocroft Journal: AIDS Date: 2015-06-19 Impact factor: 4.177
Authors: Ana C Tuyama; Feng Hong; Yedidya Saiman; Chuansheng Wang; Derya Ozkok; Arevik Mosoian; Ping Chen; Benjamin K Chen; Mary E Klotman; Meena B Bansal Journal: Hepatology Date: 2010-08 Impact factor: 17.425
Authors: Berkeley N Limketkai; Shruti H Mehta; Catherine G Sutcliffe; Yvonne M Higgins; Michael S Torbenson; Sherilyn C Brinkley; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: JAMA Date: 2012-07-25 Impact factor: 56.272
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Jason T Blackard; Jeffrey A Welge; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Denise J Jamieson; Lytt Gardner; Kenneth E Sherman Journal: Clin Infect Dis Date: 2011-01-19 Impact factor: 9.079
Authors: Suzanne M Ingle; Margaret T May; M John Gill; Michael J Mugavero; Charlotte Lewden; Sophie Abgrall; Gerd Fätkenheuer; Peter Reiss; Michael S Saag; Christian Manzardo; Sophie Grabar; Mathias Bruyand; David Moore; Amanda Mocroft; Timothy R Sterling; Antonella D'Arminio Monforte; Victoria Hernando; Ramon Teira; Jodie Guest; Matthias Cavassini; Heidi M Crane; Jonathan A C Sterne Journal: Clin Infect Dis Date: 2014-04-24 Impact factor: 9.079
Authors: Vincent Lo Re; Craig W Newcomb; Dena M Carbonari; Jason A Roy; Keri N Althoff; Mari M Kitahata; K Rajender Reddy; Joseph K Lim; Michael J Silverberg; Angel M Mayor; Michael A Horberg; Edward R Cachay; Gregory D Kirk; Mark Hull; John Gill; Timothy R Sterling; Jay R Kostman; Marion G Peters; Richard D Moore; Marina B Klein; H Nina Kim Journal: J Acquir Immune Defic Syndr Date: 2019-09-01 Impact factor: 3.731
Authors: Kenneth E Sherman; Enass Abdel-Hameed; Susan D Rouster; Mohamed Tarek M Shata; Jason T Blackard; Parham Safaie; Barbara Kroner; Liliana Preiss; Paul S Horn; Shyam Kottilil Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Heidi M Crane; Mary E McCaul; Geetanjali Chander; Heidi Hutton; Robin M Nance; Joseph A C Delaney; Joseph O Merrill; Bryan Lau; Kenneth H Mayer; Michael J Mugavero; Matthew Mimiaga; James H Willig; Greer A Burkholder; Daniel R Drozd; Rob J Fredericksen; Karen Cropsey; Richard D Moore; Jane M Simoni; W Christopher Mathews; Joseph J Eron; Sonia Napravnik; Katerina Christopoulos; Elvin Geng; Michael S Saag; Mari M Kitahata Journal: AIDS Behav Date: 2017-07
Authors: Jessica L Castilho; Megan Turner; Bryan E Shepherd; John R Koethe; Sally S Furukawa; Carmen E Bofill; Stephen Raffanti; Timothy R Sterling Journal: AIDS Res Hum Retroviruses Date: 2019-09-17 Impact factor: 2.205
Authors: Rachel A Bender Ignacio; Adrienne E Shapiro; Robin M Nance; Bridget M Whitney; Joseph A C Delaney; Laura Bamford; Darcy Wooten; Maile Y Karris; William C Mathews; Hyang Nina Kim; Jeanne Keruly; Greer Burkholder; Sonia Napravnik; Kenneth H Mayer; Jeffrey Jacobson; Michael Saag; Richard D Moore; Joseph J Eron; Amanda L Willig; Katerina A Christopoulos; Jeffrey Martin; Peter W Hunt; Heidi M Crane; Mari M Kitahata; Edward R Cachay Journal: AIDS Date: 2022-05-06 Impact factor: 4.632
Authors: Mandana Khalili; Wendy C King; David E Kleiner; Mamta K Jain; Raymond T Chung; Mark Sulkowski; Mauricio Lisker-Melman; David K Wong; Marc Ghany; Arun Sanyal; Richard K Sterling Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 20.999
Authors: H Nina Kim; Robin M Nance; Vincent Lo Re; Michael J Silverberg; Ricardo Franco; Timothy R Sterling; Edward R Cachay; Michael A Horberg; Keri N Althoff; Amy C Justice; Richard D Moore; Marina Klein; Heidi M Crane; Joseph A Delaney; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771
Authors: Michael J Vinikoor; Edford Sinkala; Roma Chilengi; Lloyd B Mulenga; Benjamin H Chi; Zude Zyambo; Christopher J Hoffmann; Michael S Saag; Mary-Ann Davies; Matthias Egger; Gilles Wandeler Journal: Clin Infect Dis Date: 2017-05-15 Impact factor: 9.079
Authors: Daniel Fuster; Kaku So-Armah; Debbie M Cheng; Sharon M Coleman; Natalia Gnatienko; Dmitry Lioznov; Evgeny M Krupitsky; Matthew S Freiberg; Jeffrey H Samet Journal: Curr HIV Res Date: 2021 Impact factor: 1.341